Skip to main content
×
×
Home

Low dose typical antipsychotics – a brief evaluation

  • David Taylor (a1)
Extract

Atypical antipsychotics have, according to some, revolutionised the treatment of schizophrenia. These drugs are claimed to be better tolerated than older typical drugs largely because of their lower propensity to cause acute extrapyramidal side-effects (EPSE). Some atypicals cause little or no hyperprolactinaemia. Some are suggested to cause less tardive dyskinesia than typical drugs. Many are claimed to improve, to a relatively greater extent, negative and cognitive symptoms of schizophrenia. In addition, one atypical, clozapine, is unarguably more effective than typical drugs in the treatment of refractory schizophrenia. Atypical drugs are now sometimes recommended as first choice treatment for schizophrenia (Lieberman, 1996; Taylor et al, 2000).

  • View HTML
    • Send article to Kindle

      To send this article to your Kindle, first ensure no-reply@cambridge.org is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about sending to your Kindle. Find out more about sending to your Kindle.

      Note you can select to send to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be sent to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

      Find out more about the Kindle Personal Document Service.

      Low dose typical antipsychotics – a brief evaluation
      Available formats
      ×
      Send article to Dropbox

      To send this article to your Dropbox account, please select one or more formats and confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your <service> account. Find out more about sending content to Dropbox.

      Low dose typical antipsychotics – a brief evaluation
      Available formats
      ×
      Send article to Google Drive

      To send this article to your Google Drive account, please select one or more formats and confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your <service> account. Find out more about sending content to Google Drive.

      Low dose typical antipsychotics – a brief evaluation
      Available formats
      ×
Copyright
This is an Open Access article, distributed under the terms of the Creative Commons Attribution (CC-BY) license (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted re-use, distribution, and reproduction in any medium, provided the original work is properly cited.
References
Hide All
Ayd, F. J. (1972) Comparative trial of low dose haloperidol and fluphenazine in office patients. Diseases of the Nervous System, 32, 192195.
Baldessarini, R. J., Cohen, B. M. & Teicher, M. H. (1988) Significance of neuroleptic dose and plasma level in the pharmacological treatment of psychoses. Archives of General Psychiatry, 45, 7991.
Bebbington, P. (1999) Caution, not cost behind drug debate. Health Service Journal, 109, 21.
Beumont, P. J. V., Gelder, M. G., Friesen, H. G., et al (1974) The effects of phenothiazines on endocrine function: I. Patients with inappropriate lactation and amenorrhoea. British Journal of Psychiatry, 124, 413419.
Binder, R. L., Kazamatsuri, H. & Nishimura, T. (1987) Tardive dyskinesia and neuroleptic-induced parkinsonism in Japan. American Journal of Psychiatry, 144, 14941496.
Bollini, P., Pampallona, S., Orza, M. J., et al (1994) Antipsychotic drugs: is more worse? A meta-analysis of the published randomized control trials. Psychological Medicine, 24, 307316.
Caligiuri, M. P., Lacro, J. P., Rockwell, E., et al (1997) Incidence and risk factors for severe tardive dyskinesia in older patients. British Journal of Psychiatry, 171, 148153.
Chakos, M. H., Alvir, J. M., Woerner, M. G., et al (1996) Incidence and correlates of tardive dyskinesia in first episode of schizophrenia. Archives of General Psychiatry, 53, 313319.
Chaplin, R., Gordon, J. & Burns, T. (1999) Early detection of antipsychotic side-effects. Psychiatric Bulletin, 23, 657660.
Day, J. C., Kinderman, P. & Bentall, R. A. (1998) A comparison of patients' and prescribers' beliefs about neuroleptic side-effects: prevalence, distress and causation. Acta Psychiatrica Scandinavica, 97, 9397.
Donnelly, L. (1999) Schizophrenia patients face denial of new drug treatments. Health Service Journal, 109, 8.
Farde, L., Nordstrom, A-L., Wiesel, F-A., et al (1992) Positron emission tomographic analysis of central D1 and D2 dopamine receptor occupancy in patients treated with classical neuroleptics and clozapine. Archives of General Psychiatry, 49, 538544.
Hamner, M. B. & Arana, G. W. (1998) Hyperprolactinaemia in antipsychotic-treated patients: guidelines for avoidance and management. CNS Drugs, 10, 209222.
Hirschowitz, J., Hitzemann, R. & Vallabhajosula, S. (1997) SPECT studies of D2 occupancy in low-dose haloperidol treatment. American Journal of Psychiatry, 154, 715716.
Jeste, D. V., Lacro, J. P., Palmer, B., et al (1999) Incidence of tardive dyskinesia in early stages of low-dose treatment with typical neuroleptics in older patients. American Journal of Psychiatry, 156, 309311.
Kane, J. M. & McGlashan, T. H. (1995) Treatment of schizophrenia. Lancet, 346, 820825.
Kane, J. M. & Marder, S. R. (1993) Psychopharmacologic treatment of schizophrenia. Schizophrenia Bulletin, 19, 287302.
Kapur, S., Remington, G., Jones, C., et al (1996) High levels of dopamine D2 receptor occupancy with low-dose haloperidol treatment: a PET study. American Journal of Psychiatry, 153, 948950.
Keepers, G. A., Clappison, V. J. & Casey, D. E. (1983) Initial anticholinergic prophylaxis for neuroleptic-induced extrapyramidal syndromes. Archives of General Psychiatry, 40, 11131117.
Levinson, D. P., Simpson, G. M., Sing, H., et al (1990) Fluphenazine dose, clinical response, and extrapyramidal symptoms during acute treatment. Archives of General Psychiatry, 47, 761768.
Levinson, D. P., Simpson, G. M., Lo, E. S., et al (1995) Fluphenazine plasma levels, dosage, efficacy, and side effects. American Journal of Psychiatry, 152, 765771.
Lieberman, J. A. (1996) Atypical antipsychotic drugs as a first-line treatment of schizophrenia: a rationale and hypothesis, Journal of Clinical Psychiatry, 57 (suppl. 11), 6871.
McCreadie, R. G., Robertson, L. J. & Wiles, D. H. (1992) The Nithsdale Schizophrenia Surveys. IX: Akathisia, parkinsonism, tardive dyskinesia and plasma neuroleptic levels. British Journal of Psychiatry, 160, 793799.
McEvoy, J. P., Hogarty, G. E. & Steingard, S. (1991) Optimal dose of neuroleptic in acute schizophrenia: a controlled study of the neuroleptic threshold and higher haloperidol dose. Archives of General Psychiatry, 48, 739745.
Meltzer, H. Y. & Fang, V. S. (1976) The effect of neuroleptics on serum prolactin in schizophrenic patients. Archives of General Psychiatry, 33, 279286.
Morgenstern, H. & Glazer, W. M. (1993) Identifying risk factors for tardive dyskinesia among long-term outpatients maintained with neuroleptic medications. Archives of General Psychiatry, 50, 723733.
Muscettola, G., Barbato, G., Pampallona, S., et al (1999) Extrapyramidal syndromes in neuroleptic-treated patients: prevalence, risk factors, and association with tardive dyskinesia. Journal of Clinical Psychopharmacology, 19, 203208.
Nishikawa, T., Tsuda, A., Tanaka, M., et al (1985) Prophylactic effects of neuroleptics in symptom-free schizophrenics: roles of dopaminergic and noradrenergic blockers. Biological Psychiatry, 20, 11611666.
Palao, D. J., AraÚxo, A., Haro, J. M., et al (1996) The relationship between plasma haloperidol concentrations and clinical results. Archives of General Psychiatry, 53, 11671169.
Richardson, M. A. & Craig, T. J. (1982) The coexistence of parkinsonism-like symptoms and tardive dyskinesia. American Journal of Psychiatry, 139, 341343.
Rifkin, A., Doddi, S., Karajgi, B., et al (1991) Dosage of haloperidol for schizophrenia. Archives of General Psychiatry, 48, 166170.
Seeman, P. & Tallerico, T. (1999) Rapid release of antipsychotic drugs from dopamine D2 receptors: an explanation for low receptor occupancy and early clinical relapse upon withdrawal of clozapine or quetiapine. American Journal of Psychiatry, 156, 876884.
Stone, C. K., Garver, D. L., Griffith, J., et al (1995) Further evidence of a dose–response threshold for haloperidol in psychosis. American Journal of Psychiatry, 152, 12101212.
Taylor, D., McConnell, D., Mcconnell, H., et al (2000) The Bethlem & Maudsley NHS Trust Prescribing Guidelines (6th edn). London: Martin Dunitz.
Toenniessen, L. M., Casey, D. E. & McFarland, B. H. (1985) Tardive dyskinesia in the aged. Archives of General Psychiatry, 42, 278284.
Vanos, J., Fahy, T., Jones, P. E., et al (1997) Tardive dyskinesia: who is at risk? Acta Psychiatrica Scandinavica, 96, 206216.
Van Putten, T., Marder, S. R. & Mintz, J. (1990) A controlled dose comparison of haloperidol in newly admitted schizophrenic patients. Archives of General Psychiatry, 47, 754758.
Van Putten, T., Marder, S. R., Mintz, J., et al (1992) Haloperidol plasma levels and clinical response: a therapeutic window relationship. American Journal of Psychiatry, 149, 500505.
Volavka, J., Cooper, T. B., Czobor, P., et al (1995) Plasma haloperidol levels and clinical effects in schizophrenia and schizoaffective disorder. Archives of General Psychiatry 52, 837845.
Zimbroff, D. L., Kane, J. M., Tamminga, C. A., et al (1997) Controlled, dose–response study of sertindole and haloperidol in the treatment of schizophrenia. American Journal of Psychiatry, 154, 782791.
Recommend this journal

Email your librarian or administrator to recommend adding this journal to your organisation's collection.

BJPsych Bulletin
  • ISSN: 0955-6036
  • EISSN: 1472-1473
  • URL: /core/journals/bjpsych-bulletin
Please enter your name
Please enter a valid email address
Who would you like to send this to? *
×

Metrics

Full text views

Total number of HTML views: 3
Total number of PDF views: 1 *
Loading metrics...

Abstract views

Total abstract views: 114 *
Loading metrics...

* Views captured on Cambridge Core between 2nd January 2018 - 19th June 2018. This data will be updated every 24 hours.

Low dose typical antipsychotics – a brief evaluation

  • David Taylor (a1)
Submit a response

eLetters

No eLetters have been published for this article.

×

Reply to: Submit a response


Your details


Conflicting interests

Do you have any conflicting interests? *